Abstract
Prostaglandins (PGs) of the J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ12,14- PGJ2 (15d-PGJ2) are naturally occurring metabolites of PGD2. Among them, 15d-PGJ2 is a powerful ligand for the peroxisome proliferator-activated receptor-γ (PPARγ). 15d-PGJ2 and synthetic PPARγ ligands have been reported to exert several effects on vascular cells, such as antiproliferative, differentiation-inducing, anti-apoptotic, and anti-inflammatory effects, most of which seem to be atheroprotective, although PPARγ-independent mechanisms may be involved. Vascular endothelial cells, intimal smooth muscle cells, and cardiomyocytes express lipocalintype PGD synthase (L-PGDS) in vivo, which catalyzes the isomeric conversion of PGH2 to PGD2. L-PGDS expression in endothelial cells is stimulated by laminar fluid shear stress. PGD2 and 15d-PGJ2 are detected in the culture medium of endothelial cells exposed to shear stress. Serum and urinary levels of L-PGDS increase in diseases with vascular injuries, such as hypertension and diabetes. Based on these findings, we hypothesize that PGs of the J2 series are physiological substances produced in the vascular wall to protect vascular cells from injurious stimuli and to repress inflammatory reactions. If this hypothesis is correct, PGJ2 family members or other similar substances may provide novel preventive and therapeutic strategies for the treatment of vascular diseases.
Keywords: Prostaglandin, L-PGDS
Current Vascular Pharmacology
Title: Prostaglandin J2 Family and the Cardiovascular System
Volume: 2 Issue: 2
Author(s): Toshiyuki Sasaguri and Yoshikazu Miwa
Affiliation:
Keywords: Prostaglandin, L-PGDS
Abstract: Prostaglandins (PGs) of the J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ12,14- PGJ2 (15d-PGJ2) are naturally occurring metabolites of PGD2. Among them, 15d-PGJ2 is a powerful ligand for the peroxisome proliferator-activated receptor-γ (PPARγ). 15d-PGJ2 and synthetic PPARγ ligands have been reported to exert several effects on vascular cells, such as antiproliferative, differentiation-inducing, anti-apoptotic, and anti-inflammatory effects, most of which seem to be atheroprotective, although PPARγ-independent mechanisms may be involved. Vascular endothelial cells, intimal smooth muscle cells, and cardiomyocytes express lipocalintype PGD synthase (L-PGDS) in vivo, which catalyzes the isomeric conversion of PGH2 to PGD2. L-PGDS expression in endothelial cells is stimulated by laminar fluid shear stress. PGD2 and 15d-PGJ2 are detected in the culture medium of endothelial cells exposed to shear stress. Serum and urinary levels of L-PGDS increase in diseases with vascular injuries, such as hypertension and diabetes. Based on these findings, we hypothesize that PGs of the J2 series are physiological substances produced in the vascular wall to protect vascular cells from injurious stimuli and to repress inflammatory reactions. If this hypothesis is correct, PGJ2 family members or other similar substances may provide novel preventive and therapeutic strategies for the treatment of vascular diseases.
Export Options
About this article
Cite this article as:
Sasaguri Toshiyuki and Miwa Yoshikazu, Prostaglandin J2 Family and the Cardiovascular System, Current Vascular Pharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570161043476384
DOI https://dx.doi.org/10.2174/1570161043476384 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Signal Transduction Research of the Angiotensin II Type-1 Receptor: Protein Kinases, Vascular Dysfunction and Structural Requirement
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology Renal Cytochrome P450-Derived Eicosanoids and Hypertension
Current Hypertension Reviews MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Editorial (Thematic Issue: New Technological and Clinical Trends in Blood Pressure Theranostics: Is it Time to Consider a Spatio-Temporal Approach?)
Current Pharmaceutical Design Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Lamotrigine as an Effective Treatment for Behavioral Disorders
Letters in Drug Design & Discovery The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews